SANUWAVE Health, Inc.
$15.60
+1.3%SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
High confidenceValuation multiple is compressed (P/E 11.3).
Valuation inputs: P/E 11.3, earnings yield +8.8%, momentum +1.3%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is acceptable (ROE +7.3%, ROIC +19.4%).
Profitability stack: net margin +26.8%, ROE +7.3%, ROIC +19.4%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +95.7%, momentum +1.3%, net margin +26.8%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
SANUWAVE Health, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
SANUWAVE Health, Inc. Fair Value Envelope
SANUWAVE Health, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
SANUWAVE Health, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
CapEx Intensity
Capital-intensive operations require significant reinvestment. Monitor whether CapEx is maintenance or growth-oriented.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
SANUWAVE Health, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.
Debt-to-Equity Ratio
High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.
Working Capital
Positive working capital, but relatively tight. The company should monitor cash flow carefully.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
SANUWAVE Health, Inc. Street Expectations Map
Wall Street analysts project that SNWV stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 54.00, with estimates ranging from a low of 53.00 to a high of 55.00.
The consensus 1-year price target stands at 54.00, with estimates ranging from a low of 53.00 to a high of 55.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
SANUWAVE Health, Inc. Insider Positioning
During the last 12 months, insiders have purchased $303K and sold $6.95M worth of SNWV shares, resulting in $6.65M of net selling activity.
3 Months
0
0.00
112.7K
2.00M
-2.0M
-$2.00M
3-6 Months
0
0.00
162.8K
4.95M
-4.9M
-$4.95M
6-9 Months
1.3K
38.36K
0
0.00
+38K
+$38K
9-12 Months
8.1K
265.08K
529
11.90K
+253K
+$253K
Top Buyers
Miller Ian D.
Director
$58K
Tyler James
Director
$52K
Bazar Gregory Matthew
Director
$52K
Frank Morgan C.
Director, 10 Percent Owner, Officer: Chief Executive Officer
$52K
Blizard Jeffrey
Director
$52K
Top Sellers
Manchester Management Co Llc
Other: Director By Deputization
$4.95M
Opaleye Management Inc.
10 Percent Owner
$2.00M
Stegagno Peter
Officer: Chief Operating Officer
$12K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $6.65M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
SNWV has not reported any dividend yield values in the available annual periods.
snwv Dividend History
Learning Layer
Related Guides
Build conviction on SNWV by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.